Philip Burchard has been CEO of Merz Pharmaceuticals since July 2012. During his tenure, Merz has refocused its strategy on Aesthetic Medicine and Neurotoxins. This has led to early successes such as a realignment of R&D generating a new pipeline of products as well as the acquisitions of three companies, Ulthera, Anteis and Neocutis. Another focus area of Merz is geographic expansion. As a consequence, a number of affiliates have been created in a number of countries. Merz continues to invest into Aesthetics and Neurotoxins and aspires to become the most admired, trusted and innovative company in these fields. Prior to joining Merz, Philip Burchard worked at AstraZeneca for ten years and Prior to that at Hoechst/Aventis for fifteen years. He worked mostly in commercial roles of increasing responsibility in sales and marketing at headquarters as well as in a number of countries in Europe, the US, Asia and Latin America. Philip Burchard holds a business administration degree from the European Business School in Germany.